CONFIDENTIAL

# REPORT : CUTANEOUS COMPATIBILITY STUDY

## SINGLE PATCH TEST

CLINICAL STUDY FOR THE VERIFICATION OF THE GOOD CUTANEOUS COMPATIBILITY OF A COSMETIC INVESTIGATIONAL PRODUCT, AFTER A SINGLE APPLICATION TO THE SKIN OF THE BACK AND UNDER OCCLUSIVE PATCH FOR 48 HOURS, IN THE ADULT SUBJECT

| | | |
|---|---|---|
| INVESTIGATIONAL PRODUCT | : | **EMULSIÓN CALMANTE CON MENTOL** (ref.: CILMTI003) |
| LABEX CODE PRODUCT NUMBER | : | E190243 376004 |
| EXPERIMENTAL PROTOCOL | : | Nº PE190010G, of 11 January 2019 |
| REPORT | : | Nº E190243RE version 1, of 21 June 2019 |
| START OF OBSERVATIONS | : | 17 June 2019 |
| END OF OBSERVATIONS | : | 19 June 2019 |

| STUDY MONITOR | STUDY RESPONSIBLE | INVESTIGATOR |
|---|---|---|
| A. MULA<br>**LABORATORIOS MONTPLET, S.L.U.**<br>Vía Trajana, 53-55<br>08020 BARCELONA | B. RAIS<br>Ph.D. Biological and Medical Sciences<br>European Registered Toxicologist - EUROTOX<br>**Labex**<br>Passeig Sant Joan, 76,<br>08009 BARCELONA | Dr. J. GALVE<br>Dermatologist<br>**Address of Investigation:**<br>**Labex**<br>Passeig Sant Joan, 76,<br>08009 BARCELONA |

**Document of 7 pages**

## AUTHENTICATION

The study subject of the present report was conducted under my responsibility, in compliance with the experimental protocol, and in accordance with Labex Standard Operating Procedures and in the spirit of the general principles of the Good Clinical Practices.

I have read this report and I agree with its content.



**Dr. J GALVE, M.D.**
**Dermatologist Investigator**
**Study Director**

All observations and numerical data obtained during this study are reported in the present document. I have read this report, I certify that these data are an accurate reflection of the results obtained and I agree with its content.

**Badr RAIS**
**Technical Manager**

## QUALITY CONTROL

This study was performed in conformity with the Standard Operating Procedures of the Laboratoire d'Expertise Clinique Espagne, the protocol signed with the sponsor and "in the spirit" of the general principles of the Good Clinical Practices published by I.C.H. (Topic E6 : CPMP/ICH/135/95).

Audits of clinical studies are conducted every 6 months for each type of study. They are intended to check the correct application of the procedures during the study. The results of these audits are subject to reporting to the Investigator(s) and the Responsible for the Study.

Labex Quality Unit confirms the compliance of this report with the data generated during the study.

Barcelona, 21 June 2019

**Amina RADI**
**Auditor Quality**

| PROTOCOL | |
|---|---|
| STUDY OBJECTIVE | To check the good compatibility of an investigational product, after a single application, on the skin of the back and under occlusive patch for 48 hours, in the adult subject. |
| TYPE OF STUDY | Cutaneous compatibility study. |
| STUDY RELEVANCE | Cutaneous irritation can be defined as an attack of the skin integrity, with lesions of the epidermis and an inflammatory reaction of the dermis, expressed by macroscopically visible phenomena, mainly redness (erythema), up to edema.<br>In man, the study known as "Single Patch Test" (occlusive application of a product to the skin 48 hours), allows to check, the good cutaneous compatibility in 10 to 20 subjects (absence of cutaneous primary irritation) after a single application followed by a clinical examination performed according to a given numerical scale. |
| INCLUSION CRITERIA | Number of subjects : 10<br>Sex : female or male<br>Age : 18 to 70 years old<br>Healthy subjects with history of atopy: 25%* maximum<br>** proportion commonly admitted for this population.* |
| METHODOLOGY | **Application modalities of the investigational product:**<br>• Areas: back, between the hips and the shoulders (area without naevi, redness or imperfection),<br>• Quantity: 0.02 gr over a 50-mm² area (occlusive patch "Small Finn Chambers on Scanpor"),<br>• Application conditions: product as supplied under occlusive patch (Finn Chambers),<br>• Duration and frequency: single application, for about 48 hours.<br><br>**Evaluation modalities:**<br>• Clinical evaluations, about 30 minutes after removal of the patches: readings are done and compared to those obtained with the "negative" control (patch alone or with a filter paper disc and/or vehicle),<br>• Cutaneous irritation quantification, according to a given numerical scale (see appendix: erythema, edema, papulae / vesicles / bullae / pustules, dryness / desquamation, detergent effect, reflectivity), by the method of the differences (product - control). |
| ANALYSIS OF RESULTS AND INTERPRETATION | **Determination of the index of Primary Cutaneous Irritation (P.C.I.): mean of the weighted sum of scoring obtained on the whole panel:**<br>• Erythema: factor 1<br>• Edema, papulae, vesicles, bullae, pustules: factor 2<br>• Dryness, detergent effect, reflectivity: factor 0.5.<br><br>**Interpretation of the results obtained**, under the adopted experimental conditions based on:<br>• The P.C.I. obtained<br>• The type of investigational product<br>• Statistics of Labex (positioning of the compatibility in comparison to products of the same type). |

## CONCLUSION

**From the results obtained under the adopted experimental conditions (single application to the skin of the back and under occlusive patch for 48 hours), the CUTANEOUS COMPATIBILITY of the investigational product designated as "EMULSIÓN CALMANTE CON MENTOL (ref.: CILMTI003)" in the adult subject, may be judged, on the whole, VERY GOOD.**

Barcelona, 21 June 2019

**B. RAIS**
**Ph.D. Biological and Medical Sciences**
**European Registered Toxicologist - EUROTOX**
**Technical Manager**



**Dr. J GALVE**
**Dermatologist Investigator**
**Study Director**

This study was conducted by Labex, managed by Mr. B. RAÏS, Eurotox Registered Toxicologist.